Gut microbiota and metabolome distinctive features in Parkinson disease: Focus on levodopa and levodopa-carbidopa intrajejunal gelOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This study examined the effect of antiparkinsonian medication, specifically levodopa (LD) and levodopa-carbidopa intestinal gel (LCIG), on the gut microbiota and fecal metabolome in Parkinson disease (PD). Fecal DNA was analyzed using next-generation sequencing of the V3 and V4 regions of the 16S rRNA gene. Fecal metabolic extracts were also evaluated using gas chromatography mass spectrometry to characterize metabolome differences across treatment groups.
Who was studied?
The study included 107 patients with a clinical diagnosis of Parkinson disease. Patients were divided into three groups: an LCIG group (n = 38) receiving levodopa-carbidopa intrajejunal gel, an LD group (n = 46) receiving oral levodopa, and a Naive group (n = 23) not taking any antiparkinsonian medications. This design allowed comparison of gut microbiota composition across different treatment exposures within a PD population.
What were the most important findings?
Multivariate analysis showed that the LCIG group had a significantly higher abundance of Enterobacteriaceae, Escherichia, and Serratia compared to the LD group. Compared to the Naive group, the LD group showed a reduction of Blautia and Lachnospirae. The LCIG group additionally showed an increase in Proteobacteria and Enterobacteriaceae alongside a reduction in Firmicutes, Lachnospiraceae, and Blautia relative to the Naive group.
What are the greatest implications of this study?
The findings suggest that the route and form of levodopa therapy, oral versus intrajejunal gel, are associated with distinct gut microbiota profiles in Parkinson disease. The reduction of Blautia and Lachnospiraceae, taxa associated with short-chain fatty acid production, alongside enrichment of Enterobacteriaceae in LCIG-treated patients points to a treatment-related shift toward a less favorable microbial composition. These distinctive features may warrant further investigation into how PD medication choice shapes gut microbial and metabolic health over the course of treatment.